GLP1R and type 2 diabetes mellitus: Many randomised controlled trials (RCTs) [4, 11, 12] have used this new technology to monitor blood glucose control and side effects with oral ADM [i.e., metformin, sulfonylurea, SGLT-2 inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and DPP-4 inhibitors] among adults with T2D.